Immunosuppression strategies in liver transplantation patient; patients with hepatocellular carcinoma.
Τίτλος | Immunosuppression strategies in liver transplantation patient; patients with hepatocellular carcinoma. |
Publication Type | Journal Article |
Year of Publication | 2017 |
Authors | Giakoustidis, A. E., & Giakoustidis D. E. |
Journal | Immunotherapy |
Volume | 9 |
Issue | 2 |
Pagination | 197-206 |
Date Published | 2017 01 |
ISSN | 1750-7448 |
Λέξεις κλειδιά | Animals, Antineoplastic Agents, Carcinoma, Hepatocellular, Graft Rejection, Humans, Immunosuppression, Immunosuppressive Agents, Liver Transplantation, Recurrence, TOR Serine-Threonine Kinases |
Abstract | Hepatocellular carcinoma (HCC) consists the main primary malignant tumor of the liver. There is an underlining liver cirrhosis mainly attributed to chronic hepatitis B virus or hepatitis C virus, alcoholic liver disease, nonalcoholic steatohepatitis and other pathologic conditions. Liver transplantation consists a radical management, treating both cancer and cirrhosis. By introducing the Milan Criteria for liver transplantation in HCC patients there was a 5-year survival escalation. Even though there is a careful selection of patients with HCC for transplantation, recurrent disease is still high. The role of immusuppression therapy is of paramount importance, in order to avoid acute and chronic graft rejection while protecting the patient from tumor recurrence. In recent years newer immunosuppressive agents such as the mTOR inhibitors are proposed, having dual properties, as both immunosuppressive and antitumors agents. |
DOI | 10.2217/imt-2016-0110 |
Alternate Journal | Immunotherapy |
PubMed ID | 28128716 |